Please assess the completion status of the following clinical trial:

Trial Title: Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's age is 18-55~* Patient has current diagnosis of schizophrenia and is experiencing an acute exacerbation of psychosis~* Patient has a history of at least three months exposure to one or more antipsychotic therapy(ies) and a prior response to antipsychotic therapy within the previous five years~Exclusion Criteria:~* Any female patient who is pregnant or breast-feeding~* Any patient presenting with concurrent dementia, delirium, mental retardation, epilepsy, drug-induced psychosis, or history of significant brain trauma~* Any patient presenting with schizoaffective disorder, bipolar disorder, acute mania, or major depression with psychotic features~* Any patient considered to be an imminent danger to themselves or others~* Any patient with hematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or substance abuse as defined by protocol~* Any patient judged by the Investigator to be inappropriate for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ITI-007 Low Dose (Type: EXPERIMENTAL): None
- ITI-007 High Dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).